A placebo-controlled (sham surgery) trial of VY-AADC01 in patients with advanced Parkinson's disease
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs AAV-hAADC (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 10 May 2017 According to a Voyager Therapeutics media release, data from two studies (CTP700238664 & CTP700238664) will help inform the design of this trial.
- 23 Nov 2016 New trial record
- 10 Nov 2016 According to Voyager Therapeutics, compnay planned to begin this trial in the fourth quarter of 2017.